当前位置:首页 > 申请书大全 > 莫西沙星治疗老年下呼吸道感染临床疗效及安全性研究:下呼吸道感染吃什么药
 

莫西沙星治疗老年下呼吸道感染临床疗效及安全性研究:下呼吸道感染吃什么药

发布时间:2019-06-14 04:36:41 影响了:

  [摘要] 目的 探讨莫西沙星治疗老年下呼吸道感染的临床疗效及安全性。 方法 将86例老年下呼吸道感染患者随机分为观察组和对照组,各43例,观察组给予莫西沙星注射液400 mg/d静脉滴注治疗,对照组给予左氧氟沙星注射液400 mg/d静脉滴注治疗。观察两组患者临床疗效、细菌清除率、症状消退时间及不良反应情况,并进行对比分析。 结果 观察组总有效率为95.35%,明显高于对照组的79.07%(P < 0.05);观察组细菌总清除率为93.55%,明显高于对照组的68.75%(P < 0.05);观察组发热、咳嗽、咳痰及肺部啰音等症状消退时间明显低于对照组(P < 0.05);两组不良反应均较轻微,且发生率比较无显著差异(P > 0.05)。 结论 莫西沙星治疗老年下呼吸道感染具有疗效好、见效快、抗菌广谱、药效持久等诸多优点,且不良反应轻微,可作为目前临床治疗老年下呼吸道感染的一种首选药物。
  [关键词] 老年下呼吸道感染;莫西沙星;左氧氟沙星;细菌清除率
  [中图分类号] R56 [文献标识码] A [文章编号] 1673-7210(2012)07(b)-0062-03
  Clinical efficacy and safety study of Moxifloxacin in the treatment of elderly patients with lower respiratory tract infection
  ZHENG Yongyi
  Department of Internal Medicine, Sanxiang Hospital of Zhongshan City, Guangdong Province, Zhongshan 528463, China
  [Abstract] Objective To study the clinical efficacy and safety of Moxifloxacin in the treatment of elderly patients with lower respiratory tract infection. Methods 86 cases of elderly patients with lower respiratory tract infection were randomly divided into the observation group and the control group, with 43 cases in each group, the observation group was given Moxifloxacin Injection 400 mg/d intravenous infusion therapy, the control group was given Levofloxacin Injection 400 mg/d intravenous infusion therapy. The clinical efficacy of the two groups, the rate of bacterial clearance, symptoms subsided time and adverse reactions were observed, and the contrast analysis was carried on. Results In the observation group, the total effective rate was 95.35%, significantly higher than 79.07% of control group (P < 0.05); the observation group total bacterial clearance rate was 93.55%, significantly higher than 68.75% of control group (P < 0.05); fever, cough, expectoration of observation group and pulmonary rales and other symptoms subsided time were significantly lower than those of control group (P < 0.05); two groups of adverse reactions were mild, and the occurrence rate was no significant different (P > 0.05). Conclusion Moxifloxacin in the treatment of lower respiratory tract infection in elderly patients has good curative effect, quick effect, antibacterial spectrum, lasting and many other advantages, and the adverse reactions are mild, it can be presented as clinical treatment of elderly patients with lower respiratory tract infection of a first drug.
  [Key words] Senile patients with lower respiratory tract infection; Moxifloxacin; Levofloxacin; Bacterial clearance rate

猜你想看
相关文章

Copyright © 2008 - 2022 版权所有 职场范文网

工业和信息化部 备案号:沪ICP备18009755号-3